Most sickle cell disease patients who received the gene-editing therapy Casgevy have been free from vaso-occlusive crises for ...

Investing in biotech stocks isn't for everyone because the very nature of their business is fraught with risk. As a result, ...

In a report released today, Phil Nadeau from TD Cowen maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research Report). The company’s ...